To Jagannath, cure means long periods of disease-free survival as defined by minimal residual disease (MRD) criteria, 10 -5 ...

Abbreviations: BR, bendamustine plus rituximab; CLL, chronic lymphocytic leukemia; ECOG PS, Eastern Cooperative Oncology Group performance status; IGHV, immunoglobulin heavy-chain variable region; SLL ...

A recent study reveals comparable outcomes for radical cystectomy and bladder-sparing therapy in treating recurrent ...

The Alliance for Clinical Trials in Oncology has launched a randomized phase III clinical trial called RECIPROCAL (Alliance ...

The American Journal of Managed Care® ( AJMC®) hosted its annual event, Patient Centered-Oncology Care (PCOC), on September ...

Precision oncology advancements have led to new treatment options for gastric cancer, including immunotherapy and targeted ...

SynOx Therapeutics completed enrollment for the phase 3 TANGENT study of emactuzumab for tenosynovial giant cell tumors, with results expected in 2026. ALX Oncology launched a phase 1 trial of ALX2004 ...

More than two years after the FDA held a public workshop on measuring overall survival (OS) in clinical cancer trials, the agency has released a draft guidance on the topic, recommending that OS be ...

Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage companies focusing on development of first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today outlined continued ...